Averages with 5% confidence limit (LLofCi) and 95% confidence limit (ULofCI) are given for patients with PR (n=6), SD (N=6), and PD (n=11); Significance vs Early Responders: *) p=0.1; **) p=0.03; #) p=0.05; ##)p=0.0035. ‡) Significance of entire group vs. baseline: p<0.02. Abs-absolute
Tumor cell-free DNA copy number instability (CNI) to predict therapeutic response to immunotherapy prior to cycle 2 
Figure 1: Early Responders vs. Early Disease Progression after initiation of immunotherapy
Averages with 5% confidence limit (LLofCi) and 95% confidence limit (ULofCI) are given for patients with PR (n=6), SD (N=6), and PD (n=11); Significance vs Early Responders: *) p=0.1; **) p=0.03; #) p=0.05; ##)p=0.0035. ‡) Significance of entire group vs. baseline: p<0.02. Abs-absolute 
Background
Tumor cell-free DNA (cfDNA) provides minimally invasive patient specific biomarkers to monitor tumor burden. Gains and losses of chromosomal regions have been detected in plasma as copy number aberrations (CNAs). Tregs are reported to be modulated by immunotherapy (immuno). We measured CNAs changes during treatment by computing a genomic copy number instability index (CNI) of cfDNA and Treg-specific demethylation region (TSDR) as measure for Tregs% of leukocytes compared to response.
Methods
In this prospective study, prior to treatment and before each cycle, extracted plasma-DNA was subjected to shallow whole genome sequencing with a post mapping (HG19) read coverage of 24,000-fold per 5.5Mbp bin. Read counts were transformed into (log2 ratio) Zvalues, and a CNI-score was calculated. % of TSDR+ leukocytes (TSDR%) were quantified with digital PCR from PBMC DNA. Primary endpoint was best overall response by imaging (irRECIST and RECIST 1.1). Hypotheses were: a) response to immuno is reflected by CNI change vs. baseline during therapy an b) alters TSDR%. Outcome was unblinded for analysis.
Results
Of 27 enrolled patients (pts), 23 were assessable for response (Table 1) : 4 advanced melanoma (MEL), 2 renal cell carcinoma (RCC), 5 gastrointestinal, 4 pulmonary, 3 breast, 1 ovarian cancers, 3 pancreatic adenocarcinomas, and 1 sarcoma. MEL and RCC received interleukin-2, while the rest received anti-PD-1 with chemotherapy on trials. Median age was 58 years, 12 were women. CNI was measured in 69 samples. Mean baseline cfDNA was 8,076 (CI 90th :2,894-13,258cp/mL) and CNI was 2,222 (CI 90th :1,162-3,282). Pts with partial response (PR) or stable disease (SD) (n = 12) showed a significant decrease in CNI before cycle 2 (C2) (Mean: -1,386 vs.+271; p < 0.02), before cycle 3 (C3) (-2,524 vs.+698, p < 0.005), and thereafter (p < 0.002) compared to pts with disease progression (PD). Figure  1 illustrates the CNI changes on immuno vs. pre-therapeutic values for early responders (PR+SD) vs. early PD. Total cfDNA was not correlated to CNI nor to response. TSDR% showed a decrease in all patients (p < 0.02; prior to C3) with immuno, independent of response ( Figure 2 ). Figure 3 shows the prediction power of PR vs. PD by CNI over time course of treatment as ROC curves. Already after the first cycle of immuno 14 of17 patients are classified correctly, reaching an 88% accuracy before C3, which remained stable over the overviewed time course (up to 6 cycles).
Conclusions
CNI change vs. baseline predicted response before C2 approximately 3-12 weeks prior to scan results, and therefore may serve as early predictor of therapeutic response to immuno. Immuno lowers Tregs % in blood, which might reflect T-cell activation, but does not differ between outcomes.
